
8th International Electronic Conference on Medicinal Chemistry
Part of the International Electronic Conference on Medicinal Chemistry series
1–30 Nov 2022
Medicinal Chemistry, Pharmaceuticals, Drug
- Go to the Sessions
- Event Details
On behalf of the conference team of the 8th International Electronic Conference on Medicinal Chemistry, we would like to thank you for your participation by sending your contributions, being posters, slideshows or flash communications. We hope you've enjoyed it!
List of accepted submissions (253)
Id | Title | Authors | Presentation Video | Presentation Pdf | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-066140 | Dynamic Cross-Correlation Matrix (DCCM) Reveals New Insights to Discover New NLRP3 Inhibitors Useful as Anti-inflammatory Drugs | , , , | N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
The innate immune system is responsible for the body's defense against aggressive agents, mainly through activating pattern-recognition receptors (PRRs). Recognizing these agents results in an inflammatory response that activates tissue repair and eliminating the agent. Among the macromolecules related to these events are inflammasomes (inflammatory response activators), with emphasis on nucleotide-binding domain leucine-rich repeat-containing receptors protein 3 (NLRP3), in which blocking their oligomerization inhibits inflammasome activity. In this way, targeting NLRP3 represents a new approach to designing anti-inflammatory drugs. Here, molecular docking and dynamics, focusing on Dynamic Cross-Correlation Matrix (DCCM) analysis, were used to characterize significant interactions of MCC950 (known inhibitors) and their analog NP3-166 (ligand co-crystalized) with NLRP3 and generate useful information in drug design. The results showed that the compounds were stable during the MD simulation time (100 ns), demonstrated by the RMSD RMSF, Rg, SASA, and H-bond plots. Analysis of the DCCM graphs showed that more correlated movements are presented for MCC950 compared to NP3-166. In fact, the more rigid structure of MCC950 may influence the more significant interaction. A higher correlation observed in both complexes between residues 100 – 200 and 300 – 400 highlights the results obtained from the interaction analysis, showing that interaction with Ala228 and Arg578 may be essential for the inhibitory activity of the compounds. Our findings highlight that greater structural rigidity of the ligand and interactions with residues Ala228 and Arg578 may be critical for designing new NLRP3 inhibitors with anti-inflammatory potential. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-065951 | Implementation of Qbd Approach to Develop and Validate HPTLC Method for simultaneous estimation of Aliskiren, Amlodipine and Hydrochlorothiazide in Pharmaceutical Formulation | , | N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
A High performance thin layer chromatographic method for simultaneous estimation of Aliskiren, Amlodipine besylate and Hydrochlorothiazide was developed and validated as per ICH guidelines. Moreover, robustness testing was performed applying a central composite design with k factor having 2 k factorial runs, 2k axial experiments and two center points. High performance thin layer chromatographic separation was performed on aluminium plates precoated with silica gel 60F 254 and acetonitrile: methanol: strong ammonis (10:10:0.1, v/v) as optimized mobile phase. The detection wavelength for simultaneous estimation of three drugs was 250 nm. The Rf values for Aliskiren, Amlodipine besylate and Hydrochlorthiazide were 0.54, 0.32 and 0.78 for, respectively. Percent recoveries in terms of accuracy for the marketed formulation was found to be 101.3-104.4, 100.7-104 and 101.5-103.9 for, Aliskiren, Amlodipine besylate and Hydrochlorthiazide, respectively. The pooled % relative standard deviation values for repeatability studies and intermediate precision studies was found to be less than 2% for Aliskiren, Amlodipine besylate and Hydrochlorthiazide, respectively. All these three factors (methanol content, developing distance and band size) were evaluated in the robustness testing by central composite design and these were found to have an insignificant effect on the retention factor. However, methanol content in total mobile phase as a factor appeared to have significant effect on robustness, compared to band size and developing distance and hence it is important to be carefully controlled. In summary, a novel, simple, accurate and reproducible high performance thin layer chromatographic method was developed, which would be of use in quality control of these tablets. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-066508 | Synthesis of new purine nucleosides as potential metal chelators and anticholinesterase agents | , , , , , , , , , , , | N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by multiple factors such as the progressive decline of the levels of the neurotransmitter acetylcholine, and the deregulation of the homeostasis of bio-metals such as copper, zinc and iron. Acetylcholine is hydrolyzed by acetylcholinesterase and butyrylcholinesterase and the current therapeutic strategies are based on the treatment of AD patients with these enzymes’ inhibitors. Although these strategies are focused on disease’s symptomatic relief, recent studies have shown that the long-term use of these drugs may lead to disease modifying benefits. The deregulation of the bio-metals’ homeostasis has been related to oxidative stress and to the induction of Ab aggregation and of tau hyperphosphorylation and aggregation. Since AD is a multifactorial disease, discovering a multi-target drug could be an interesting challenge leading to a disease modifying therapy. In this context, mannosylpurines synthesized in our group already showed a potent butyrylcholinesterase (BChE) inhibition. Aiming at the discovery of such multitarget drug candidates, we have synthesized a new series of mannosyl and rhamnosylpurines and evaluated copper chelation and cholinesterases’ inhibition. The results obtained will be presented and discussed. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-063442 | In vitro inhibitory effects on pancreatic lipase and α-glucosidase activity by extracts and fractions of Lavandula angustifolia L. from Southern Italy | , , | N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Lavandula angustifolia is one of the most popular medicinal plants, rich source of bioactive compounds. Most of the studies on lavender had focused on its essential oil and its use as a sleep aid, calmative, fragrant, insect repellant and flavoring agent. This work is aimed at investigating, for the first time, the potential role of L. angustifolia in the management of metabolic syndrome (MetS), one of the major and escalating public-health and clinical challenge worldwide. Herein, the aerial parts of L. angustifolia, collected in June 2021 in the “Parco Nazionale del Pollino”, Southern Italy, were subjected to extraction by maceration with ethanol. Then, the total extract was partitioned with solvents at different polarity such as n-hexane, dichloromethane and ethyl acetate. Extract and fractions were evaluated for their ability to inhibit alpha-glucosidase as well as lipase. The ethanol extract remarkably inhibited a-glucosidase and lipase (IC50 of 2.55 and 30.50 microg/ml, respectively) better than the positive control acarbose and orlistat (IC50 of 35.51 and 37.12 microg/ml, respectively). The most active fraction was dichloromethane with IC50 of 14.67 and 17.64 mg/ml, against alpha-glucosidase and lipase, respectively. Taking into account obtained results, L. angustifolia could be used for formulation of new products; however, further preclinical studies will be needed to confirm its in vivo efficacy, as well as to prove the safety of the tested extracts and fractions. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-066034 | Synthesis of 4-acetamido-octahydrochromene derivatives based on (-)-isopulegol - promising analgesic agents | , , , | N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Selective modification of natural compounds is one of the most important ways to develop and search for new biologically active substances of various structural types. It was found earlier that some compounds with octahydro-2H-chromene scaffolds synthesized from monoterpenoid (-)-isopulegol demonstrated promising biological activity, e.g., analgesic, and antiviral activities, inhibitory activity against DNA repair enzyme Tdp1. The flexible method for the synthesis of octahydro-2H-chromenes derivatives is the Prins cyclization. This reaction could serve also as an initiator of a three-component tandem reaction. For example, the sequence of the Prins and Ritter reactions is one of the best synthetic methods to efficiently build six-membered fragment of 4-amidotetrahydropyran in a one-pot single step reaction. In this work we have developed a method for synthesis of chiral 4-acetamido-octahydro-2H-chromenes. We used tandem Prins-Ritter reaction between (-)-isopulegol and a set of ketones in acetonitrile. Desired products were formed as a mixture of 4R/4S diastereomers, where 4S one is a major isomer. Development of new analgesic agents with high activity and low toxicity is important task. It is known that the heterocyclic compounds synthesized from (–)-isopulegol exhibit analgesic activity. In the study of the analgesic activity of the synthesized compounds in vivo, we found that a number of derivatives showed high analgesic activity reliably and not inferior in efficiency to the reference drug sodium diclofenac administered at a similar dose. |
Keynote Presentations
-
Patient-centric drug product design: case studies for special populations
By
-
In the heart of cardio-oncology: the targets and biomarkers of anticancer drugs cardiotoxicity
By
-
Small molecule inhibitors of bacterial quorum sensing
By
-
By
, , , -
A potential blueprint for the design of biased ligands for aminergic GPCRs
By
-
C-Glucosyl Flavone Derivatives as Non-PAIN Therapeutic Leads for Alzheimer’s Disease
By
-
A Chemical Strategy to Improve Bioavailability of Glypromate Peptide-Conjugates
By
, ,Hugo F. Costa-Almeida, , ,José E. Rodríguez-Borges -
Resveratrol-loaded glycosylated liposomes for targeting bacteria
By
, , , , , , , , , , , , , , , -
In the heart of cardio-oncology: the targets and biomarkers of anticancer drugs cardiotoxicity
By
-
Virtual screening and drug repurposing: together against worm-borne diseases
By
, , , ,Yujie Sun,Dilini Amarasinghe, ,Vitor de Alme Almeida, -
The combined use of AuNP and NIR radiation enables cytosolic protein delivery
By
, , ,Anna Lladó,Pere Serra,Dobryna Zalvidea, ,
Welcome from the Chairs
Dear Colleagues,
Following the great success of the previous editions organized under the excellent chairmanship of Dr. Jean Jacques Vanden Eynde, we are pleased to cordially invite you to join us at 8th International Electronic Conference on Medicinal Chemistry, sponsored by the MDPI open access journal Pharmaceuticals. This platform seeks to provide a discussion forum for scientists from all over the world for recent developments and innovative ideas in Medicinal Chemistry. This will give students, researchers, and experts the opportunity to share their latest theories, results, models, and applications in this multidisciplinary area of knowledge. This is an entirely on-line conference that will be held during the month of November at https://ecmc2022.sciforum.net/. No registration fee is charged to participants, and there is the added advantage that there is no cost of flights, hotels, etc.
The conference will be organized around the aims and scope of the journal Pharmaceuticals, which include the following general topics:
Small molecules as drug candidates
Biomolecules, natural products, phages, and cells as therapeutic tools
Biological targets and biomarkers
Radiopharmaceutical sciences, radiochemistry, (hybrid) imaging, and nuclear medicine
Pharmacokinetics and pharmacodynamics
Pharmaceutical preparations and drug delivery
The format of the conference is as follows. Researchers are invited to provide a short abstract (250 words maximum without figures and without references) online at https://sciforum.net/user/submission from now until 21 September 2022 30 September 2022. Each participant can submit only one abstract as a presenting author and a maximum of three submissions per research group. All authors will be notified by 1 October 2022 with regard to the acceptance status of their abstract, at which point they will be asked to present their work (in English) in the form of a poster, a slideshow, or a video using the templates provided by the conference (see Instructions for Authors). All accepted submissions will be displayed online, open for discussion, comments, and questions, during the entire conference, at https://ecmc2022.sciforum.net/, on 1–30 November 2022.
All participants will be invited to submit a full paper describing their work, which would be peer reviewed and, upon acceptance, published in a Special Issue “Selected Papers from the 8th International Electronic Conference on Medicinal Chemistry (ECMC2022)” covering the event in Pharmaceuticals (ISSN 1424-8247) sponsor of the conference. A 20% discount on the Article Processing Charge will be applied.
The most outstanding works, as selected by the scientific committee, will be rewarded with grants offered by the sponsoring journal Pharmaceuticals.
We look forward to engaging in exciting discussions and hearing new ideas and perspectives from experts in the field. All participants are welcome to join the online conference.
Kind regards,
Dr. Alfredo Berzal-Herranz
Prof. Dr. Maria Emília Sousa
Call for Participations
The members of the Scientific Committee are pleased to announce this Call for Participation for the 8th International Electronic Conference on Medicinal Chemistry and to invite each researcher working in the exciting fields of medicinal chemistry and drug-related sciences to share their recent results with their colleagues all over the world.
The Conference will cover a wide range of aspects involved in drug discovery and development. A non-exhaustive list of topics that will be considered includes:
- ADMET
- Animal experimentation
- Assay development
- Biomarkers
- Biomolecules
- Biosensors
- Biotechnology
- Chemical synthesis
- Clinical studies and side effects reports
- Combinatorial chemistry
- Drug delivery (including bioconjugates and prodrugs)
- High throughput screening
- Hit identification
- Imaging techniques
- In silico experiments
- In vitro and in vivo studies
- Lead optimization
- Omics
- Pharmaceutical analysis
- Scale-up
- Structure–activity relationships
Participation in the 8th International Electronic Conference on Medicinal Chemistry is absolutely free of charge for contributors and visitors. Researchers are invited to provide a short abstract (250 words maximum without figures and without references) online at https://www.sciforum.net/login from now until 21 September 2022 30 September 2022. Each participant can submit only one abstract as a presenting author and a maximum of three submissions per research group. Authors will be notified before 1 October with regard to the acceptance status of their abstract, at which point the author(s) will be asked to present their work (in English) in the form of a poster, a slideshow, or a video using the templates provided by the conference (see Instructions for Authors). All accepted submissions will be displayed online, at https://ecmc2022.sciforum.net/, on 1–30 November 2022.
Authors will be invited to publish their work as a review or a research article at a discounted price, in a Special Issue of the journal Pharmaceuticals.
The Scientific Committee looks forward to receiving contributions in response to this call and will be glad to provide any further information to interested parties. Questions may be addressed to the Pharmaceuticals editorial office at [email protected].
We thank you in advance for your attendance to this conference and look forward to a stimulating exchange.
Submission Guidelines
For information about the submission procedure and the preparation of a full presentation, please refer to the "Instructions for Authors".
Event Chairs

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), Spain

Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal
Event Committee

School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Portugal

Department of Environmental Biology, Sapienza University of Rome, Rome, Italy

Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Sweden

Helmholtz-Zentrum Dresden-Rossendorf (HZDR) e.V., Institute of Radiopharmaceutical Cancer Research, Germany

PharmaCampus Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Germany

Department of Pathology & Microbiology, University of Nebraska Medical Center, USA

Center of Health Sciences, Laboratory of Molecular Modeling and Computational Structural Biology, Federal University of Rio de Janeiro, Brazil

Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Finland

Department of Pharmacy, University of Chieti, Italy

Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, USDA‐ARS, 800 Buchanan St., Albany, CA 94710, USA

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), PTS Granada, Av. Conocimiento, Granada, Spain

Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, Italy

Centro de Química Estrutural, Instituto Superior Técnico, Universidade Técnica de Lisboa, Portugal

Department of Biomolecular Sciences, University of Urbino Carlo Bo Piazza del Rinascimento, Italy

Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Turkiye
Invited Speakers

Institute for Biological System, Secondary office of Rome-Reaction Mechanisms, c/o Chemistry Dept Sapienza University of Rome, Italy

Center of Chemistry and Biochemistry, Faculdade de Ciências, Universidade de Lisboa, Portugal

Grupo de Pesquisas Químico-Farmacêuticas, GPQFfesp, Chemical and Pharmaceutical Sciences, Institute of Environmental, Federal University of São Paulo, Brazil

Department Oral Immunology and Infectious Diseases, School of Dentistry, University of Louisville, USA

Microbiology and Infectious Diseases, School of Systems Biology, George Mason University, USA

Theoretical Medicinal Chemistry, Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Germany

Group of Receptor Ligands for Molecular Imaging, European Institute for Molecular Imaging (EIMI), Muenster University, Germany

Group of Chemical biology of peptides and proteins, Department of Molecular Biology, Instituto de Parasitologia y Biomedicina "Lopez-Neyra" Spain

UCIBIO/REQUIMTE, Associate Laboratory i4HB - Institute for Health and Bioeconomy, MedTech-Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Portugal

IQ, Laboratório de Modelagem Molecular (LabMMol) - Sala 609, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, Cidade Universitária, Rio de Janeiro, Brazil

School of Pharmacy and School of Chemistry, University College Cork, Ireland

Docent in Structural Biology and Computational Biochemistry, Pharmaceutical Sciences Laboratory & Structural Bioinformatics Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Finland

School of Chemistry, Trinity College Dublin, Ireland

UCIBIO-REQUIMTE, Rede de Química e Tecnologia,Porto University, Portugal
Instructions for Authors
Submission should be completed online by the authors by registering with https://sciforum.net/ and using the “Start New Submission” function once logged into the system.
- Scholars interested in participating in the conference can submit their abstract (250 words maximum without figures and without references) online at this website until 21 September 2022 30 September 2022.
- Based on the submitted abstract, the conference committee will conduct a pre-evaluation of whether a contribution from the authors of the abstract will be welcome for 8th International Electronic Conference on Medicinal Chemistry. All authors will be notified by 1 October 2022 with regard to the acceptance status of their abstract.
- If the abstract is accepted for this conference, the author will be invited to prepare a full description of their work in the form of a poster, slideshow, or video at their best convenience, until the submission deadline of 12 October 2022.
- Posters must be uploaded as a PDF file using the Poster_template.pptx file available at the end of this section.
- Slideshows must be uploaded as a PDF file using the PPT_template.pptx file available at the end of this section.
- Flash communications (5 minutes) and communications (10-20 minutes) must be uploaded as an mp4/.webm/.ogg (max size: 250Mb) file (video) using the PPT_template.pptx file available at the end of this section.
- Tips for authors: if you would like to prepare a video based on your PowerPoint presentation, you may use the "record slide" function in PowerPoint.
This must be uploaded before 12 October 2022, for a final check and approval. Each work will be directed to the appropriate panel (posters, slideshows, flash communications, communications) by the Conference Office.
Contributions will be displayed on the website using Sciforum.net’s proprietary slides viewer and will be accessible at https://ecmc2022.sciforum.net/ at the time of the conference. They can be prepared in exactly the same way as for any traditional conference where research results can be presented. Contributions must be converted to PDF format before submission, so that they can be easily and automatically converted to be displayed online.
The organization of posters is left completely up to the authors, provided that they use the conference’s template.
The accepted contributions will probably be published as one dedicated volume in the MDPI Medical Sciences Forum journal. Publication of proceedings paper is free of charge.
Note: Before publication, Medical Sciences Forum journal will review accepted papers using the powerful text comparison tool: iThenticate. This procedure aims to prevent scholarly and professional plagiarism.
Submissions with a high repetition rate and lack of novelty will not be published in the conference proceedings.
Certificate of Attendance : After the event, the participants of ECMC 2022 will be able to download an electronic Certificate of Attendance by logging in to your Sciforum personal account. Once you are logged-in, go to your profile and click on 'My certificates'. A list of all Sciforum events you have attended is available and you simply have to click on "Download" next to the correct event.
We recommend the following organization for your slideshow, poster or video, using the Conference’s template:
Slides- Length of the presentation: no more than 30 slides
- Slides can be prepared the same way as for any traditional conference. They should be converted into a PDF format before submission.
- Slide 1 (strictly one slide): Title, authors’ names, affiliation(s), email address of corresponding author, logos of the laboratory and/or institution (not mandatory).
- Slide 2 (strictly one slide): Graphical abstract; repeat the title of the presentation but avoid other text as far as possible.
- Slide 3 (strictly one slide): Abstract (max. 250 words) and 3–5 keywords, separated by semicolons.
- Slide 4 and following slides: These should contain (in the given sequence) Introduction, Results and Discussion, Conclusions.
- Last slide: Acknowledgments, and logos of sponsors (not mandatory).
Posters will be available on this conference website during and after the event. Like papers presented on the conference, participants will be able to ask questions and make comments about the posters. Posters can be presented without an accompanying proceedings paper.
The poster should be in PDF format
- The minimum size for images is 148 mm × 210 mm (horizontal × vertical) at 300 dpi.
- The content of the poster should be a comprehensive presentation of your accepted submission.
- No copyright issues with any elements in the poster.
Uploaded files:
Event Awards
The following awards will be offered by our organizers.
The Awards
Number of Awards Available: 5
The open access peer-reviewed Journal Pharmaceuticals will offer each one award (400 CHF) to reward the best poster, the best slideshow, the best flash communication and the best communication, and 500 CHF to reward the best invited lecture. All submissions will be considered, independently of the session (general and round table). The best works will be selected by the members of the Scientific Committee.Number of Awards Available: 1
One free 1-day hands on/testing using microwaves offered by Microwave Technologies Consulting. Selection will be made by the Company following strict scientific criteria.Conference Secretariat
Ms. Amber Zhao
Ms. Jennifer Wang
Email: [email protected]
S1. Opening session

Prof. Dr. Maria Emília Sousa

Dr. Alfredo Berzal-Herranz
S2. Invited lectures

Prof. Dr. Maria Emília Sousa

Dr. Alfredo Berzal-Herranz
S3. General

Dr. Jong Heon Kim
S4. Small molecules as drug candidates

Prof. Dr. Mary J. Meegan

Dr. Daniela De Vita
S5. Biomolecules as therapeutics

Prof. Dr. Amélia Pilar Rauter

Dr. Cristina Romero-López
S6. Emerging technologies in drug discovery

Prof. Dr. Joachim Jose

Prof. Dr. Osvaldo Andrade Santos-Filho
S7. Radiopharmaceuticals

Dr. Klaus Kopka
S8. Pharmaceutical development

Prof. Dr. Jessica Rosenholm
Winner Announcement
On behalf of the chairs of the 8th International Electronic Conference on Medicinal Chemistry (ECMC-8), we are pleased to announce the winners of the Conference Award:
Best Poster Award
- Marie Hanot et al., "Development of New Anti-virulence Agents to Tackle Multi-resistant Pseudomonas Aeruginosa".
Marie Hanot is a second-year Ph.D. student in Medicinal Chemistry, in the team of Pr. Pascal Sonnet (AGIR, UR4294) at the Faculty of Pharmacy of the University of Picardie Jules Verne (France). Marie’s research focuses on the development of anti-virulence agents to combat pseudomonal multi-drug resistance. Marie holds a B.Sc. degree in chemistry from the same institution as well as a M.Sc. degree in Chemistry, Biology and Drugs from the University of Strasbourg (France).
Best Slideshow Award
- Maddalena Paolillo et al., "Binding to Proteins of the Pharmacologically Active Bis(Maltolato) Oxidovanadium(IV)".
The presenting author, Maddalena Paolillo, is a first-year Ph.D. student in Chemical Sciences from Department of Chemical Sciences of University of Naples Federico II (Italy). She is working under the supervision of Prof. Antonello Merlino and Prof. Filomena Sica.
She holds a master’s degree in chemical sciences (2022), with a thesis on the refinement of crystal structures of adducts formed upon reaction of model proteins with a vanadium compound of medical interest. The topic of her Ph.D. is focused on the study of the mechanism of action of different V-based drugs by analyzing, both in solution and at solid state, their interaction with biological macromolecules.
Best Flash Communication Award
- Fabian Krutzek et al., "Small Molecule Radiotracers for PET Imaging of PD-L1 with Copper-64”.
Fabian Krutzek studied Chemistry at the University of Heidelberg and obtained 2019 his Master degree in organic chemistry. Currently he is a fourth-year PhD student at the Helmholtz Center Dresden-Rossendorf under supervision of Prof. Dr. Klaus Kopka. His research project focuses on design, synthesis, and evaluation of small molecule-based radiotracers for imaging PD-L1 in cancer patients. This project requires a high level of synthetic organic chemistry, with up to 25 synthetic steps per molecule. In the interdisciplinary field of medicinal radiochemistry, he developed skills in radiochemical labeling and obtained basic knowledge in computational methods as well as cell-based assays. Through collaboration with biologists, he gained theoretical knowledge on the conduction and analysis of data from animal studies. Currently in the final months of his Ph.D. studies, he plans to pursue post-doctoral studies abroad in a related field of organic chemistry.
Best Communication Award
-Ana Marta de Matos et al., "C-Glucosyl Flavone Derivatives as Non-PAIN Therapeutic Leads for Alzheimer’s Disease".
Ana Marta de Matos graduated in Biochemistry in 2011 at FCUL and completed her M.Sc. degree in Medicinal Chemistry at FFUL in 2013. She then returned to FCUL where she pursued her Ph.D. in Organic Chemistry with a focus on the synthesis and biological evaluation of new sugar-based polyphenols with bioactivity against type 2 diabetes and Alzheimer’s disease. During her path as a Ph.D. student, she spent nine months at Eli Lilly’s Neuroscience Research Centre in Windlesham, UK, where she worked closely with some of the best Medicinal Chemists in the World. She completed her Ph.D. in 2019, published her results in high-quality peer-reviewed scientific journals in the field, and won the FCiências.ID award for Best Ph.D. Thesis in Chemistry in 2019. In July 2021, Ana received a research contract to initiate her career as an independent researcher at Centro de Química Estrutural (CQE), from the Institute of Molecular Sciences (IMS), FCUL. One year later, she was awarded a contract in the highly competitive FCT call 'Scientific Employment Stimulus 2022’, having also been nominated as shadow coordinator of the Carbohydrate Chemistry Group of CQE, FCUL. Ana Marta is currently interested in developing new carbohydrate-based compounds against infections caused by multidrug-resistant Gram-negative bacteria.
Best Invited Lecture Award
Dr Tim O’Sullivan received his BSc Degree in Industrial Chemistry from the University of Limerick in 1997. He then went on to do a PhD in natural products synthesis under the supervision of Prof. Lew Mander at the Research School of Chemistry of the Australian National University from 1998 to 2001. He worked as a postdoctoral researcher on the synthesis of Tamoxifen analogues with Prof. Mary Meegan in Trinity College Dublin from 2001 before taking up another postdoctoral fellowship with Prof. Pat Guiry in University College Dublin on the synthesis of novel Lipoxin analogues in 2003 . Following a period as research manager in UCD, he was appointed as Lecturer in Pharmaceutical Chemistry in the School of Pharmacy/Department of Chemistry/ABCRF in UCC in 2006. He is a member of the Royal Society of Chemistry, the Marie Curie Alumni Association and COST Action 'CA21145 European Network for diagnosis and treatment of antibiotic-resistant bacterial infections (EURESTOP)'. His research is focussed on developing new methods and strategies for the synthesis of bioactive, natural products. The underlying goal in this work is to improve upon existing techniques and to discover novel methods for assembling complex molecular targets. The ultimate aim is to apply this knowledge to the development of more potent analogues of existing compounds, with a view to producing pharmaceutically relevant therapeutic agents.
One free 1-day hands on/testing using microwaves offered by Microwave Technologies Consulting
-Rosa Tundis et al., "In vitro inhibitory effects on pancreatic lipase and α-glucosidase activity by extracts and fractions of Lavandula angustifolia L. from Southern Italy ".
-Maria Mernea et al., "A molecular docking study on natural compounds as anxiolytics and antidepressants ".
S2. Invited lectures
Show all published submissions (10) Hide published submissions (10)
Submissions
List of Papers (10) Toggle list
S4. Small molecules as drug candidates
S5. Biomolecules as therapeutics
S6. Emerging technologies in drug discovery
S7. Radiopharmaceuticals
Show all published submissions (3) Hide published submissions (3)
Submissions
List of Papers (3) Toggle list